BOSTON, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Thomas Hughes, Ph.D., Chief Executive Officer, is scheduled to present a company overview at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 3:30pm ET at the Waldorf Astoria in New York. A live audio webcast of the presentation will be available on Zafgen's website at www.zafgen.com.
About Zafgen, Inc.
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in Prader-Willi syndrome, hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen was founded in 2005 to explore novel approaches to obesity therapeutics, including agents known to inhibit MetAP2 that had been found to drive unprecedented weight loss and metabolic improvements in mice. The company is located in Boston, MA.
CONTACT: Investor Relations Contact: Shauna (Wreschner) Elkin (212) 850-5613 Shauna.Elkin@fticonsulting.comSource:Zafgen, Inc.